Savara Inc. filings document a clinical-stage biopharmaceutical issuer focused on rare respiratory diseases and its development of molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis. The record includes Nasdaq-listed common stock disclosures, Regulation FD corporate presentations, clinical and regulatory updates, operating and financial results, and material-event reports tied to business operations.
Recent filings also cover definitive proxy materials, board and compensation matters, shareholder voting matters, lease obligations, and debt arrangements under a loan and security agreement. These disclosures describe Savara's capital structure, financing covenants, material agreements, governance practices and corporate reporting obligations.
Schedule 13G filing for Savara Inc. (SVRA) shows that a group of Venrock Healthcare Capital Partners funds and related managers/individuals has crossed the 5% disclosure threshold.
- Reporting group: Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, and principals Nimish Shah and Bong Y. Koh.
- Aggregate beneficial ownership: 9,021,507 common shares.
- Ownership breakdown: 1,997,410 shares (VHCP III); 199,772 shares (VHCP Co-Investment III); 6,824,325 shares (VHCP EG).
- Percentage of class: 5.2% of Savara’s 172,836,922 outstanding shares (as of 13 May 2025).
- Voting & dispositive power: 0 shares sole; 9,021,507 shares shared—indicating coordinated but passive ownership. Filing is under Rule 13d-1(c), not 13D, so the group states no intent to influence control.
- Date of event triggering filing: 30 June 2025; filing signed 08 July 2025.
The disclosure signals that Venrock, a life-science–focused investor, holds a meaningful but non-controlling position in Savara. Investors often view recognized sector specialists taking a >5% stake as a vote of confidence, yet the filing itself does not imply any change in Savara’s strategy, capital structure, or governance. The stake is passive and therefore has limited immediate operational impact.